In another study, Li et al. engineered a bispecific nanobody (BsNb PX4) targeting CXCR4 and PD-L1 to reprogram the pancreatic tumor microenvironment via selective disruption of the SDF-1/CXCR4 signaling axis. This evidence concerns the gene CXCR4 and pancreatic neoplasm.